For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink: https://www.kuickresearch.com/report-global-breast-cancer-predictive-genetic-testing-market-outlook-2022.php
Table of Contents
-
Cancer Susceptibility Testing
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing
-
Breast Cancer Susceptibility
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes
-
Hereditary Breast Cancer Genes
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 and CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes
-
Breast Cancer Susceptible Syndromes
4.1 Hereditary Breast and Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome
-
Cancer Susceptibility Testing Essentials
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing
-
Genetic Cancer Susceptibility Testing
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling
-
Management of Hereditary Risk
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy
-
Economical, Ethical and Social Aspects
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing
-
Global Prevalence of Breast Cancer
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity
-
Prevalence over Geographic Regions
10.1 Prevalence in Developed Regions
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2 Prevalence in Developing Regions
10.2.1 China
10.2.2 India
10.2.3 Africa
-
Preface of Monetary Prospects
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing
-
Aspects of Cancer Susceptibility Market
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market
-
Global Breast Cancer Predictive Genetic Testing Market Dynamics
13.1 Accelerative Parameters
13.2 Challenges
-
Global Breast Cancer Predictive Genetic Testing Market Future Aspects
-
Competitive Landscape
15.1 Cancer Genetics
15.2 Invitae
15.3 Iverson Genetics
15.4 Myriad Genetics
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.8 Quest Diagnostics
15.9 Roche
15.10 Thermo Fisher Scientific
Figure 1-1: Layout of Traditional and Advanced Cancer Susceptibility Testing
Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
Figure 3-2: Percentage of BRCA1 Gene Mutations and Other Genes for Breast Cancer
Figure 3-3: Breast Cancer Risk by Carriers and Non-Carriers with Growing Age
Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
Figure 3-5: Percentage of Risk Factors of Breast Cancer and Variability of Penetrance Genes
Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
Figure 6-1: The Concept of Breast Cancer Risk Assessment and Management
Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
Figure 9-1: Global – Demonstration of Incidence and Mortality Rate of Breast Cancer
Figure 9-2: Global – Comparative Percentage of Risk of Developing Breast Cancer in Women
Figure 9-3: US – Prevalence of BRCA Mutation Percentage among White Population
Figure 9-4: UK – Prevalence of BRCA Mutations Percentage among White Population
Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
Figure 10-1: US – Rates of Incidence and Mortality Breast Cancer in US as per 100,000
Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
Figure 10-3: Europe – Percentage of Incidence and Mortality of Breast Cancer
Figure 10-4: UK – Rate of Breast Cancer Incidence Related to Age, 2014
Figure 10-5: Europe – Percentage of BRCA1 Mutation in High Risk Families
Figure 10-6: Canada – Percentage of All New Cancer Cases and Breast Cancer Cases, 2016
Figure 10-7: Canada – Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
Figure 10-8: Japan – Incidence Rates of Breast Cancer as per 100,000
Figure 10-9: China – Incidence and Mortality Rates in Chinese Population, 2015
Figure 10-10: India – Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
Figure 10-11: Central Africa – Age Adjusted Incidence and Death Rates for Breast Cancer
Figure 11-1: US – Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-2: UK – Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-3: Canada – Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-4: Japan – Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-5: Australia and New Zealand – Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-6: China – Cost of Breast Cancer Susceptibility Testing in China (US$)
Figure 11-7: India – Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-8: Singapore – Cost of BRCA Testing and Mastectomy
Figure 12-1: Myriad’s – Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing and Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing and Direct to Consumer Test
Figure 12-5: Global andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia andndash; BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global – Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global – Major Challenges of Breast Cancer Susceptibility Market
Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age